SCHEMBL2193574

SCHEMBL2193574

CSc1ccccc1Nc1nc(O)ccc1N

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KHK P50053 2/20 0.39
KMT2A Q03164 3/20 0.36
TP53 P04637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 2/20 0.36
GBA1 P04062 1/20 0.35
BRAF P15056 1/20 0.35
MAPKAPK2 P49137 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
ALDH1A1 P00352 4/20 0.34
ALOX15 P16050 2/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTK2 Q05397 1/20 0.34
MAPT P10636 2/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192393 0.83 HTT (0.39) KHKKMT2ABRAFTRPV1ALDH1A1
SCHEMBL2192476 0.78 MAPT (0.44) KMT2ANPSR1MEN1ALDH1A1HTT
SCHEMBL2193744 0.78 PDE5A (0.46) KMT2ANPSR1HSD17B10MEN1ALDH1A1
SCHEMBL2196525 0.77 EPHX2 (0.48) KMT2ATP53NPSR1HSD17B10MEN1
SCHEMBL2191805 0.76 KMT2A (0.46) KMT2AMEN1ALDH1A1L3MBTL1MAPT
SCHEMBL2191767 0.76 NUDT1 (0.47) KMT2ATP53NPSR1MEN1ALDH1A1
SCHEMBL2195557 0.75 EPHX2 (0.46) KMT2ATP53NPSR1MEN1TRPV1
SCHEMBL2196576 0.74 HSD17B10 (0.35) KHKKMT2AHSD17B10MEN1BRAF
SCHEMBL2192571 0.74 MAPT (0.50) KMT2AMEN1ALDH1A1MAPT
SCHEMBL2194676 0.74 NUDT1 (0.33) KMT2ATP53HSD17B10MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 KHK 2055/4885KMT2A 3713/4885TP53 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.